comparemela.com

Latest Breaking News On - Yale medical - Page 3 : comparemela.com

Imetelstat Offers Benefits for Patients With MDS Who Are Red Blood Cell–Transfusion Dependent

The past year has offered new hope for patients with lower-risk myelodysplastic syndromes. Besides imetelstat, which has an FDA deadline for action of June 2024, the agency approved luspatercept, which has a different mechanism of action.

vimarsana © 2020. All Rights Reserved.